Clinical Trial Update: A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. [Phase 2]

View source ↗

Summary

Phase II pilot study evaluating molecular factors predicting hematologic response in myelodysplastic syndrome patients treated with deferasirox; trial terminate…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• Deferasirox (Deferasirox)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2018-07-05